Androgen-deprivation therapy in men with metastatic prostate cancer: Less may not necessarily be more

Asian Journal of Andrology

Volumn 15, Issue 4, 2013, Pages 445-446

  Ng Tang Fui, Mark ^a   Grossmann, Mathis ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CLINICAL PRACTICE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANILIDES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TOSYL COMPOUNDS;

EID: 84880128366     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.57     Document Type: Article

References (8)

1. Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40: 655-71.
2. Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl 2012; 14: 187-92.
3. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90.
4. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-25.
5. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903.
6. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how shoul. The side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74: 289-93
7. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL et al. Bone and metabolic health in patients with nonmetastatic prostate cancer who are receiving androgen deprivation therapy.Med J Aust 2011; 194: 301-6.
8. Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardised management guidelines. Andrology 2013 (in press).